The purpose of this study is to determine if a new diagnostic test, the Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel, is suitable to determine the presence of SARS-CoV-2, Influenza A, Influenza B, or Respiratory Syncytia Virus in respiratory samples. A US Food and Drug Administration cleared test will be used to compare and the determine validity of the results of the Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel. About 2000 subjects will participate in this study. This study uses competitive enrollment. This means that once enrollment goals are met, no new subjects will be enrolled. The visit takes no more than 30 minutes.
Must have had signs of a respiratory tract infection within the last 7 days, when you agree to participate, the procedures will occur while you are at your visit. No additional visits will be required.
Symptoms may include:
Fever
Chills
Runny nose or congestion
Muscle or body aches
Headache and/or feeling excessively tired
New loss of taste or smell
Nausea
Vomiting or diarrhea
New or worsening cough or sore throat
Decrease in appetite
Shortness of breath or difficulty breathing or wheezing
Other